Infectious Diseases News and Research

RSS

Incidence of septicemia increasing among service members, study finds

The annual incidence rates of primary diagnosed septicemia among active component service members increased nearly 580 percent from 2004 to 2012, according to a new study.

6 Sep 2013

Researchers hope to protect humans from another deadly outbreak like HIV

Throughout Asia, humans and monkeys live side-by side in many urban areas. An international research team from the University of Washington, Fred Hutchinson Cancer Research Center and Jahangirnagar University has been examining transmission of a virus from monkeys to humans in Bangladesh, one of the world's most densely populated countries.

5 Sep 2013

High-income and better hygiene countries exhibit much higher rates of Alzheimer's

New research has found a "very significant" relationship between a nation's wealth and hygiene and the Alzheimer's "burden" on its population. High-income, highly industrialised countries with large urban areas and better hygiene exhibit much higher rates of Alzheimer's.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Research on long-lived proteins may lead to better understanding of molecular basis of aging

Proteins are the chief actors in cells, carrying out the duties specified by information encoded in our genes. Most proteins live only two days or less, ensuring that those damaged by inevitable chemical modifications are replaced with new functional copies.

4 Sep 2013

Large study shows effective test for diagnosis of C-Diff infection

The largest study of its kind has shown the most effective test for the diagnosis of Clostridium difficile (C-Diff), a bacterial infection which causes 15,000-20,000 deaths a year in hospitals in the United States.

4 Sep 2013

Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

...

3 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Scientists estimate minimum of 320,000 viruses in mammals

Scientists estimate that there is a minimum of 320,000 viruses in mammals awaiting discovery. Collecting evidence of these viruses, or even a majority of them, they say, could provide information critical to early detection and mitigation of disease outbreaks in humans.

3 Sep 2013

Scientists determine new strategy to estimate total viral diversity in mammals

EcoHealth Alliance, a nonprofit organization that focuses on local conservation and global health issues, and the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health announced a new strategy to identify the total number of wildlife viruses that could potentially cause emerging disease outbreaks that threaten both public and wildlife health.

3 Sep 2013

Researchers identify origin of human TB

Tuberculosis remains one of deadliest infectious diseases of humans, killing 50% of individuals when left untreated. Even today, TB causes 1-2 million deaths every year mainly in developing countries. Multidrug-resistance is a growing threat in the fight against the disease.

2 Sep 2013

New quick test promises to reduce economic, health burden of syphilis cases in Latin America

Demystifying the chemical processes that create a wine's aroma, and the invaluable potential application of that understanding in winemaking, is the new objective of scientists in Uruguay who, with European partners, also recently sequenced the genome of the high-value Tannat grape, from which "the most healthy of red wines" are fermented.

2 Sep 2013

Holistic approach to understand and treat TB

For years, physicians around the world have watched as strain after strain of the deadly bacteria Mycobacterium tuberculosis evolves resistance to drugs.

2 Sep 2013

Researchers develop model that completes bridge between cellular and human studies of schizophrenia

Schizophrenia is one of the most devastating neurological conditions, with only 30 percent of sufferers ever experiencing full recovery. While current medications can control most psychotic symptoms, their side effects can leave individuals so severely impaired that the disease ranks among the top ten causes of disability in developed countries.

31 Aug 2013

BP and headache drug effectively speeds up treatment of TB

Infectious disease experts at Johns Hopkins have found, in studies in mice, that a drug better known as a treatment for high blood pressure and headaches effectively speeds up treatment of TB when added to the standard, daily antibiotic regimen. Test animals were cured in four months instead of the usual six.

30 Aug 2013

Researchers identify novel mechanism that particular superbug uses to fend off antibiotic

Investigators working to stem the spread of antibiotic-resistant bacteria have taken a major step in their efforts to develop new treatments.

29 Aug 2013

Barber pole worm genome provides essential platform to understand drug resistance in worms

Researchers have identified five enzymes that are essential to the survival of a parasitic worm that infects livestock worldwide and is a great threat to global food security. Two of these proteins are already being studied as potential drug targets against other pathogens.

29 Aug 2013

Research findings may help scientists develop anthrax treatments for humans

Researchers at the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute, both part of the National Institutes of Health, have identified the cells in two distinct areas of the body that are simultaneously targeted for damage by anthrax toxins, eventually causing illness and sometimes death. Their findings, which appeared online today in Nature, are based on testing in mice.

29 Aug 2013

FDA categorizes Cepheid's Xpert MTB/RIF test as 'Moderate Complexity' under CLIA

Cepheid today announced the U.S. Food & Drug Administration has categorized Cepheid's Xpert MTB/RIF test as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments.

28 Aug 2013

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network, are published today in The Lancet Diabetes & Endocrinology.

28 Aug 2013

Infectious Diseases News and Research

Incidence of septicemia increasing among service members, study finds

Researchers hope to protect humans from another deadly outbreak like HIV

High-income and better hygiene countries exhibit much higher rates of Alzheimer's

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Research on long-lived proteins may lead to better understanding of molecular basis of aging

Large study shows effective test for diagnosis of C-Diff infection

Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Scientists estimate minimum of 320,000 viruses in mammals

Scientists determine new strategy to estimate total viral diversity in mammals

Researchers identify origin of human TB

New quick test promises to reduce economic, health burden of syphilis cases in Latin America

Holistic approach to understand and treat TB

Researchers develop model that completes bridge between cellular and human studies of schizophrenia

BP and headache drug effectively speeds up treatment of TB

Researchers identify novel mechanism that particular superbug uses to fend off antibiotic

Barber pole worm genome provides essential platform to understand drug resistance in worms

Research findings may help scientists develop anthrax treatments for humans

FDA categorizes Cepheid's Xpert MTB/RIF test as 'Moderate Complexity' under CLIA

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Industry Focus: Infectious Diseases eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News